Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCL7A shRNA
- Development stage
- Unknown
- Lead developer
- Dana-Farber Cancer Institute
- Modality
- Viral-delivered RNAi → In Vivo RNAi → Gene Silencing → Gene Therapies, RNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
BCL7A shRNA is a short hairpin RNA (shRNA) research tool designed to silence the expression of the BCL7A gene through RNA interference. BCL7A is a member of the canonical m-SWI/SNF (BAF) chromatin remodeling complex and is frequently lost in primary multiple myeloma (MM) cells. In preclinical research, BCL7A shRNA is used to model this loss, which results in increased DNA accessibility at specific genomic regions and the activation of the IRF4 oncoprotein. The knockdown of BCL7A leads to enhanced IRF4-dependent transcriptional activity, promoting a more proliferative phenotype in myeloma cells. This tool is primarily utilized in in-vitro and in-vivo models to investigate the molecular mechanisms of myeloma pathogenesis and the development of IRF4 dependency.
- Other names
- BCL7A short hairpin RNABCL-7A short hairpin RNABCL 7A short hairpin RNAsh-BCL7Ash-BCL-7Ash-BCL 7A
02
Targets
BCL7A (B-cell CLL/lymphoma 7 protein family member A)
Beyond the preview
Go deeper on BCL7A shRNA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCL7A shRNA.